Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients.
The Journal of antimicrobial chemotherapy（2023）
摘要
These data provide additional evidence to support molnupiravir as a suitable alternative when other COVID-19 antivirals cannot be given.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要